Omniose

Founded as an early-stage biotechnology company, Omniose is dedicated to developing next-generation polysaccharide conjugate vaccines aimed at combating serious bacterial threats. Utilizing a proprietary bioconjugation platform, Omniose's core mission is to expand the range of bacterial targets that can be addressed with bioconjugate vaccines. Their innovative approach involves single cells that simultaneously produce a polysaccharide antigen along with an engineered protein, enhancing the efficacy and scope of vaccines against infectious diseases.

Omniose has garnered attention for its cutting-edge technology and potential impact on public health. The company has attracted notable investors and advisors from the biotechnology sector, contributing to its rapid development and promising outlook. Key achievements include advancing their proprietary in vivo conjugating technology and expanding their portfolio of vaccine candidates. Omniose's work holds significant promise for reducing the burden of bacterial infections globally, positioning them as a pivotal player in the field of vaccine innovation.